August 22nd, 2019
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers.
Should I buy Novartis stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading plan that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Novartis stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Novartis stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 7 ratings published for NVS stock in the last month. The general sentiment of these ratings is bearish for NVS stock, with 5 negative ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-5||JPMorgan Chase & Co.||n/a||Sell|
|2019-7-23||Kepler Capital Markets||Buy||Hold|
|2019-4-10||Morgan Stanley||Equal Weight||Underweight|
|2019-1-29||JPMorgan Chase & Co.||n/a||Sell|
|2019-1-2||JPMorgan Chase & Co.||Neutral||Underweight|
|2019-1-16||JPMorgan Chase & Co.||n/a||Sell|
Novartis stock analysis
Novartis ended today at $89.00 and slightly fell a disappointing -1.24%.
Shares of Novartis closed today at $89.00 and slightly fell a disappointing -1.24%. On April NVS price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. On July/18, NVS hit new all time highs, pushing higher previous ATH of $93.65 recorded on June. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
Novartis ended this week at $89.00 and decreased an unpleasant -0.53%. This was the 5th red week in a row, sliding in full a -5.17%. By mid July NVS skyrocketed a super good 5.74% in just one week.
Observing the weekly chart, NVS marked an uptrend of rising tops and rising bottoms. Since its last top by mid July at $95.00, price slid and bounced up back from $86.74. Breaking down under $86.74 would cancel the current uptrend and it might test lower supports. Note that $95.00 might act as a resistance line. Not so far away is the last all-time high Novartis marked by mid July. Early October, SMA20w and SMA40w crossed up triggering a rise of 19.91%. Late April NVS price bounced up over the SMA of 20 weeks that acted as support stopping new slides.
Novartis stock price history
Novartis stock went public on November 7th, 1996 with a price of $13.471. Since then, NVS stock surged a 560.70%, with a yearly average of 25.50%. If you had invested right after NVS's IPO a $1,000 in Novartis stock in 1996, it would worth $5,607.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Novartis stock historical price chart
NVS stock reached all-time highs on Jul 18th with a price of $95.00.
Novartis stock price target is $105.00How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we only found 1 price prediction for Novartis stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn January, Novartis failed to meet the forecasts of the analysts and reported an unpleasant EPS of $1.24 per share when experts were expecting $1.33.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Novartis annual sales jumped an excellent 6.05% to $53,166.00 million USD from $50,135.00 marked in 2017. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) escalated a 8.36% to 23.72%.
|2013||$48,290 M||-||$8,520 M17.6%||-|
|2014||$53,634 M||11.07%||$10,210 M19.0%||19.84%|
|2015||$50,387 M||-6.05%||$17,783 M35.3%||74.17%|
|2016||$49,436 M||-1.89%||$6,712 M13.6%||-62.26%|
|2017||$50,135 M||1.41%||$7,703 M15.4%||14.76%|
|2018||$53,166 M||6.05%||$12,611 M23.7%||63.72%|
Quarterly financial resultsNovartis reported $13,664.00 million in sales for 2018-Q4, a 4.14% improvement compared to previous quarter. Reported quarter income marked $1,195.00 million with a profit margin of 8.75%. Profit margin decreased a -3.62% compared to previous quarter when profit margin was 12.37%. When comparing revenues to same quarter last year, Novartis sales marked a good growth and inched a 3.80%.
|2017-Q2||$12,050 M||-||$1,950 M16.2%||-|
|2017-Q3||$11,950 M||-0.83%||$2,000 M16.7%||2.56%|
|2017-Q4||$13,164 M||10.16%||$1,976 M15.0%||-1.20%|
|2018-Q1||$12,929 M||-1.79%||$2,025 M15.7%||2.48%|
|2018-Q2||$13,452 M||4.05%||$7,768 M57.7%||283.60%|
|2018-Q3||$13,121 M||-2.46%||$1,623 M12.4%||-79.11%|
|2018-Q4||$13,664 M||4.14%||$1,195 M8.7%||-26.37%|
|2019-Q1||$11,455 M||-16.17%||$1,766 M15.4%||47.78%|
Novartis ownershipWhen you are planning to invest in a stock, it's always worth to check its ownership structure.
Novartis shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.00% of all shares.
In case of Novartis stock, 11.69% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NVS stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Novartis:
|Market cap||$203.8 B||$149.4 B||$77.9 B||$101.3 B||$349.9 B|
|Total shares||2,290.0 M||1,760.0 M||1,630.0 M||2,490.0 M||2,660.0 M|
|Float shares||2,150.0 M||1,750.0 M||1,630.0 M||2,440.0 M||2,630.0 M|
|- Institutional holdings (%)||11.7%||76.5%||75.0%||11.0%||69.2%|
|- Insider holdings (%)||0.0%||0.7%||0.1%||0.0%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Thursday, August 22nd, 2019|
|Day range||$88.89 - $89.63|
|Average true range||$1.63|
|50d mov avg||$91.07|
|100d mov avg||$87.04|
|200d mov avg||$82.37|
Novartis performanceTo better understand Novartis performance you must compare its gains with other related stocks in same sector or industry. For Novartis, the benchmark is made against , Bristol-Myers Squibb, GlaxoSmithKline, , Merck, Pfizer, and Teva Pharmaceutical Industries.
Novartis competitorsWe picked a few stocks to conform a list of Novartis competitors to review if you are interested in investing in NVS:
- Bristol-Myers Squibb (BMY)
- GlaxoSmithKline (GSK)
- Merck (MRK)
- Pfizer (PFE)
- Teva Pharmaceutical Industries (TEVA)
Latest Novartis stock news
- Seeking AlphaNovartis' Accelerated Review Sets Up A Potential Catalyst For FDA ApprovalJuly 25, 2019
- Seeking AlphaNovartis: A Transformation Story Not To Miss In 2019June 28, 2019
- Seeking AlphaNovartis Makes Substantial Pipeline Progress On A Couple Of FrontsJune 13, 2019
- Seeking AlphaNovartis Kisqali Might Have A Path Forward To Take On Pfizer's IbranceJune 11, 2019
- Seeking AlphaNovartis And Axovant Might Jointly Be Holding The Most Promising Neurodegeneration Drug In DevelopmentJune 4, 2019